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ABSTRACT
Triplex-forming oligonucleotides (TFOs) are syn-
thetic DNA code-reading molecules that have been
demonstrated to function to some extent in chro-
matin within cell nuclei. Here we have investigated
the impact of DNA nuclear environment on the
efficiency of TFO binding. For this study we have
used locked nucleic acid-containing TFOs (TFO/
LNAs) and we report the development of a rapid
PCR-based method to quantify triplex formation. We
have first compared triplex formation on genes
located at different genomic sites and containing
the same oligopyrimidine oligopurine sequence.
We have shown that efficient TFO binding is
possible on both types of genes, expressed and
silent. Then we have further investigated when gene
transcription may influence triplex formation in
chromatin. We have identified situations where for
a given gene, increase of transcriptional activity
leads to enhanced TFO binding: this was observed
for silent or weakly expressed genes that are not or
are only slightly accessible to TFO. Such a tran-
scriptional dependence was observed for integrated
and endogenous loci, and chemical and biological
activations of transcription. Finally, we provide
evidence that TFO binding is sequence-specific as
measured on mutated target sequences and that up
to 50% of chromosomal targets can be covered
by the TFO/LNA in living cells.
INTRODUCTION
Sequence-selective compounds that target chromosomal
DNA provide strategies for probing and modulating gene
structure and function in living systems. Since nuclear
DNA is typically bound to histones and tightly packed into
chromatin, the binding and activity of these reagents must
occur in this environment. One strategy to target determined
genomic sites is based on triplex-forming oligonucelotides
(TFOs). TFOs recognize oligopyrimidine oligopurine
sequences in DNA by binding in the major groove of the
double-helix and base triplets are formed via Hoogsteen
hydrogen bounds with the oligopurine strand. Structural
requirements inﬂuence the design of TFOs and has led to
the classiﬁcation in different subtypes: TFOs containing
C and T nucleotides, also named pyrimidine TFOs, bind in
parallel orientation via Hoogsteen hydrogen bonds [(T,C)-
motif] and TFOs containing G and A or T nucleotides
[(G,A)- and (G,T)-motif] mainly bind in antiparallel orienta-
tion via reverse Hoogsteen bonds. TFOs have been shown to
interfere with DNA-associated functions such as transcrip-
tion, replication, repair and recombination [for reviews see
(1,2)]. In addition to studies that demonstrate site-speciﬁc
activity in a cellular context and which then support the
ability of TFOs to target chromosomal sites, direct demon-
strations of triplex formation in cell nuclei have also been
reported (3–11). In some of these studies, quantitative assess-
ments of TFO target binding has been developed [for a
review see (1)]. These works show that in a cellular environ-
ment there are still many impediments to efﬁcient triplex
formation. Chromatin structure is one of them since it may
preclude access to target sequences. However the mecha-
nisms enabling TFO binding to DNA sequences in chromatin
are still largely unexplored. To address this question, in vitro
studies using reconstituted mono- and di-nucleosomes have
been performed and have shown that TFOs did not form
triplexes on sequences already covered by nucleosomes,
except at sites located towards the extremities of the nucleo-
somal DNA fragments [for a review see (12)]. Concerning
the mechanisms of TFO binding to chromosomal DNA
in cells, the data are very few and sometimes apparently
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inﬂuence triplex formation (7) and transcriptional depen-
dence was observed in one system (8) and not in two
others (3,5).
In this report the objectives are to provide mechanistic
insights to the targeting of chromosomal DNA with TFOs, in
order to enhance the potency of triplex-based strategies and
to propose novel applications of TFOs. We chose to character-
izetheimpactoftargetDNAenvironmentontriplexformation,
by studying TFO binding in two types of situations. TFO bind-
ing was evaluated on the same oligopyrimidine oligopurine
target sequence located, (i) at different genomic sites, so that
binding in different chromosomal contexts was tested, or
(ii) within a determined gene in different culture conditions,
so that binding in controlled DNA states was evaluated. On
one hand we show for the ﬁrst time that triplex formation can
take place efﬁciently on a silent gene. On the other hand, we
clarify how and when triplex formation may depend on the
level of gene transcription. Finally we demonstrate that the
binding is sequence-speciﬁc, as evaluated on mutated target
sequences, and that up to 50% of the chromosomal targets
canbecoveredbytheTFOinlivingcells.Forthisstudypyrimi-
dine locked nucleic acid-containing TFOs (TFO/LNAs) were
used because it was demonstrated previously that TFO/LNAs
improve triplex stability and bioactivity (13–15). Our results
encourage further developments of TFO/LNAs as reagents
that target chromosomal DNA in cells, for probing chromatin
structure and function and for inducing site-directed sequence
modiﬁcations.
MATERIALS AND METHODS
Oligonucleotides
Psoralen-conjugated oligonucleotide analogues with LNA
residues were obtained from Proligo (France SAS) or Euro-
gentec (Seraing, Belgium). The 50 end of LNA-modiﬁed
TFOs, Pso-PPT and Pso-CAD (Figure 1) were modiﬁed
with a 4,50,8-trimethylpsoralen via a six or nine carbon linker,
respectively.
Cell cultures and specific treatments
The CMV(+)PPT/HeLa cells were derived from HeLa/
Tet-on cells (Clontech) that are engineered HeLa cells,
stably expressing rTet protein necessary for the expression
of doxycycline-inducible promoters. The CMV(+)PPT/HeLa
cells stably contained two reporter genes, the ﬁreﬂy luci-
ferase (Photinus pyralis) gene (luc) and the GFP gene,
under the control of a bidirectional doxycycline-inducible
CMV promoter. Parental cells, Hela/Tet-on, were electro-
porated with pPUR (Clontech) and pCMV(+)PPT/luc after
Pvu I-linearization and puromycin-resistant clones were
selected. The pCMV(+)PPT/luc plasmid derives from the
bidirectional Tet-on expression vectors (pBI-Tet vectors,
Clontech) and two 55 bp inserts containing either the
wild-type HIV-1 polypurine tract target sequence (PPT:
50-AAAAGAAAAGGGGGGA-30) or a mutated sequence
(mutGPPT: 50-AAAAGAAGGGGGGGGA-30, 4 mutations
underlined) were cloned in the 50 transcribed but untranslated
regions of the luciferase and GFP genes, downstream of the
transcription start site. Then the CMV(+)PPT/HeLa cells con-
tain the PPT and the mutGPPT sequences stably integrated
within the cellular genome, upstream reporter genes (luc
and GFP, respectively). The PPT triplex site in the luciferase
gene was found to be integrated as a single copy.
The EA.hy926 cells were derived from fusion of human
umbilical vein endothelial cells (HUVEC) with the non-
endothelial lung carcinoma A549/8 cell line (gift from
E. Dejana, Milano, Italy).
Both cell lines were grown in DMEM (Invitrogen) supple-
mented with 10% of fetal bovine serum, 2 mM glutamine,
50 U/ml of penicillin and 50 mg/ml of streptomycin. For
the culture of the CMV(+)PPT/HeLa cells, addition of
500 mg/ml of G418 and 2.5 mg/ml of puromycin was provided
to maintain the integrated target sequences.
When indicated, exponentially growing cells were incu-
bated in the presence of doxycycline (Sigma) necessary for
activation of the integrated CMV promoter [1 mg/ml for
24 h (Dox1) to 96 and 120 h (Dox2 and Dox3)], or in the
presence of Trichostatin A [TSA (Sigma) at 40 ng/ml for
60 h]. Drug and medium were renewed regularly. For TSA,
doses were chosen for CMV(+PPT)/HeLa cells and for
EA.hy926 cells to enable progression through multiple cell
divisions (16).
Cells permeabilization and triplex binding assays
Pso-TFOs were delivered to cell nuclei using two types of
permeabilization procedures.
Digitonin permeabilization: Cell nuclei were prepared
according to a digitonin-based protocol, as described
Figure 1. (A) Sequences of the oligopyrimidine oligopurine DNA targets
and of the oligonucleotides used in this study. Target sequences are indicated
in boldface (PPT and VE-CAD), as well as the mutated sequences used as
controls (mutCPPT and mutGPPT). The 50-TpA site suitable for psoralen
photoadduct formation is shown. Sequences of the psoralen-modified TFO
directed against the wild-type PPT duplex (Pso-PPT) and the VE-Cadherin
gene (Pso-CAD) are described; small letters indicate LNA nucleotides;
cytosines in italic (C and c) are methylated at position 5. (B) Chemical
structure of LNA modification.
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abilized successfully and then treated with the psoralen-
modiﬁed TFO and irradiated at 365 nm (4.5 J/cm
2).
Streptolysin-O permeabilization: Streptolysin-O (SLO; a
gift from S. Bhakdi, Johannes Gutenberg-Universita ¨t, Mainz,
Germany) was used to reversibly permeabilize cells. The
protocol used here was a modiﬁcation of a previously
described SLO-based method [(17) and Supplementary
Data]. Irradiation was performed, 4 h after SLO treatment.
Dra I digestion of digitonin-permeabilized cells
A buffer containing 50 mM HEPES, pH 7.2, 50 mM NaCl,
0.5 mM spermine, 10 mM MgCl2 and 1 mM EDTA was
used to resuspend the digitonin-permeabilized cells and for
Dra I digestion. Digestion of permeabilized cells (10
7 cells)
was performed at 37 C for 1 h in 250 ml of total sample vol-
ume with 200 U/ml of Dra I. DNA was puriﬁed and digested
for Southern blot analysis.
Analyses of Pso-TFO-induced adducts
Following irradiation triplex-induced adducts were analyzed
using different methods.
Dra I protection assay and Southern blotting. Genomic
DNA was extracted just after irradiation for puriﬁcation by
standard protocols. For the cleavage protection assay we
used a modiﬁcation of our method described previously [(3)
and Supplementary Data].
Quantitative PCR analyses. Two types of quantitative PCR
methods, real-time and competitive PCR, were used to quant-
ify the amount of unmodiﬁed DNA target after Pso-TFO
treatment which can be ampliﬁed in contrast to the cross-
linked portion (for details see Results). In both cases the
amount of target fragments in each sample was compared
to the amount of control fragments, obtained from ampliﬁca-
tion of a control region, as shown in Figure 1 and Supplemen-
tary Figure 1. Every quantitative PCR analysis was done at
least three times.
Real-time PCR (for luc, GFP, TRb, CASK, COL4A1
genes): Nuclei or cells were directly resuspended in a lysis
buffer containing 10 mM Tris–HCl, pH 8, 0.45% NP40,
0.45% Tween-20 and Proteinase K (100 mg/ml, 2 h at 55 C
and 5 min at 95 C) and then subjected to PCR analyses.
Analyses were performed with Mx3005P  Real-Time PCR
System (Stratagene) (for details see Supplementary Data).
Competitive PCR (for luc and VE-Cadherin target genes):
Puriﬁed genomic DNA was subjected to competitive PCR
[for details see (18) and Supplementary Data].
Expression analysis of the target genes
At the time of TFO treatment, total cellular RNA were pre-
pared with the RNeasy Mini kit (Qiagen). RNA was quanti-
ﬁed by RiboGreen RNA Quantitation Reagent (Molecular
Probe). cDNA for RT–PCR analysis was obtained by stan-
dard procedures, starting from an equal amount of total
RNA for each sample and quantiﬁed by real-time PCR, as
described above. Such measurements give access to the
steady state level of an RNA of interest and is used here,
either to evaluate if the gene of interest is expressed or not,
or in the case of the doxycycline-inducible luciferase gene,
to determine the relative RNA levels following different
doxycycline tretaments. The sequences of the primers were
described in Supplementary Table 1.
RESULTS
Experimental design
Targets and TFOs. As targets for triplex formation we chose
two oligopyrimidine oligopurine sequences, named PPT and
VE-CAD (Figure 1); both sequences end in a 50-TpA step,
which is appropriate for photoaddition by a psoralen moiety.
We found that the PPT sequence with the neighbouring
50-TpA step, 16 bp pair long or a 15 bp long version just
lacking the A-30 (50-AAAAGAAAAGGGGGG-30 named
PPT15), is present at different genomic loci. We studied TFO
binding on two of them: the calcium/calmodulin-dependent
serine protein kinase gene (CASK) located on chromosome
X and the thyroid hormone receptor beta gene (TRb) located
on chromosome 3. In addition, to manipulate transcription at
the TFO target site in genomic DNA, the PPT sequence was
introduced downstream a doxycycline-inducible promoter
and upstream the luciferase reporter gene (luc) and stably
integrated in the genome of HeLa/Tet-on cells. Finally, to
study the inﬂuence of transcriptional activation on TFO bind-
ing in another context, a second oligopyrimidine oligopurine
sequence was targeted in the VE-Cadherin gene located on
chromosome 16 (VE for Vascular Endothelial).
The TFOs used in this study, Pso-PPT and Pso-CAD (see
sequences in Figure 1), were linked to psoralen. They were
composed of alternating LNA and DNA nucleotides all
along the sequence, with two LNA modiﬁcations at the
30 end to increase resistance to 30-exonucleases (19). We
already described that anti-PPT TFO/LNAs have considerably
improved antigene properties compared with the isosequential
phosphodiester oligomers (15). Here we used UV irradiation
in order to produce covalent triplexes with Pso-PPT and
Pso-CAD on the corresponding DNA target. In both cases,
photo-adducts were formed at the 50-TpA-30 sequence present
at the 50 end of the oligopurine tract and the majority of lesions
was bis-adducts ( 90%) while a minority of mono-adducts
( 10%) were obtained (data not shown), as already described
with other TFO chemistries (20).
Quantification of triplex formation in genomic DNA. Our goal
is to characterize triplex formation in a quantitative manner in
different chromatin contexts. For this purpose we developed a
PCR-based approach that allows quantiﬁcation of triplex
formation whatever the targeted site in the genome. Brieﬂy
our method is based on the fact that cross-linked DNA mole-
cules such as the ones obtained after treatment by Pso-TFO
and irradiation, are not substrates for PCR ampliﬁcation
using primers located on each site of the cross-link. Real-
time PCR was used to quantify the amount of ampliﬁed
products in samples treated by Pso-TFO and irradiated.
Two sets of primers were used: one for ampliﬁcation of the
target region and another one for ampliﬁcation of a control
region lacking the target site, as schematically described on
Figure 2B. Then the relative PCR inhibition (target region/
control region) might reﬂect the level of triplex-induced
cross-links. In order to characterize this dependence we
4548 Nucleic Acids Research, 2006, Vol. 34, No. 16prepared genomic DNA with determined amounts of cross-
links and measured the relative PCR inhibition as described
above (Figure 2). The samples were prepared starting from
100% cross-linked genomic DNA that was further mixed
with untreated genomic DNA in appropriate ratios (0:1, 1:4,
1:2, 3:4, 1:0 matching 0, 25, 50, 75 or 100% of triplex-
induced adducts). We demonstrated that relative PCR inhibi-
tion was linearly correlated to the percentage of triplex-
induced lesions, that were measured by a well-validated
method, protection from enzyme cleavage and Southern
blot analysis. We also veriﬁed that the same amounts of
triplex-induced adducts were obtained with the real-time
PCR developed here and the competitive PCR assay we
reported previously (3). It is of importance that no inhibition
was detected when irradiation was omitted, demonstrating
that this type of analysis only measured the covalently
psoralen-modiﬁed DNA targets and not reversible triplex
formation that could occur independently of irradiation.
Targeting the same sequence present in different
chromosomal contexts
We exploited the fact that the same oligopyrimidine 
oligopurine sequence is present at various locations in the
human genome to investigate the inﬂuence of different chro-
mosomal contexts on the efﬁciency of TFO binding. Indeed
we chose to study three genes that contain the PPT sequence
in the transcribed region and have different expression status
in HeLa cells: the CASK gene is expressed, the TRb and the
integrated luciferase locus (luc) are not. In addition, two
mutated oligopyrimidine oligopurine genomic targets,
mutCPPT in COL4A1 gene and mutGPPT in GFP, were
used to establish TFO binding speciﬁcity (see sequences in
Figure 1). The PCR-based analysis described above was
used to determine the Pso-PPT-induced adducts in these
three target genes containing the PPT15 sequence, as well as
on the two mutated target sequences.
On naked genomic DNA, we demonstrate that the Pso-PPT
can recognize its double-stranded target present at different
locations within genomic DNA in a sequence-speciﬁc manner
and that complete coverage of the three target sites can be
obtained (Figure 3A). The speciﬁcity of TFO-induced lesions
at the PPT sequence in genomic DNA was established by the
use of another pyrimidine psoralen-conjugate TFO (Pso-
CAD) and of the two mutated target sequences described
above. Under conditions allowing almost complete modiﬁca-
tion of the PPT sequence by the Pso-PPT, no detectable triplex
formation was obtained, either with the Pso-CAD at the PPT
site or with the Pso-PPT at the mutGPPT target, and around
20% PCR inhibition was measured with the Pso-PPT at the
mutCPPT target. It is noteworthy that the COL4A1 gene
was originally chosen as one of the PPT15 containing gene.
Figure 2. Quantification of triplex formation. (A) Quantification of triplex formation by Dra I protection assay. (Upper panel) The 16 bp
oligopyrimidine oligopurine target sequence (PPT) present upstream the luciferase gene overlaps a Dra I recognition sequence (boxed); the two arrows
indicate the sites of Dra I cleavage. Dra I sites around the PPT sequence are shown and the lengths of the fragments in base pairs obtained after Dra I cleavage are
indicated. Location of the RNA probe used for Southern blot analysis is shown. (Lower panel) Naked genomic DNA of CMV(+PPT)/HeLa cells was treated with
Pso-PPT and irradiated (+hn) or not ( hn); then the DNA was analyzed by Dra I protection assay (Supplementary Data). DNA markers: (lane M), 1 kb DNA
marker (New England Biolabs); (lane P), pCMV(+PPT)/luc plasmid that was used to generate the CMV(+PPT)/HeLa cells, was treated by Pso-PPT, irradiated
and cleaved by Dra I. (B) Quantitative PCR analysis of site-directed inter-strand lesions. (Upper panel) Schematic representation of the quantitative PCR analysis
method. Regions containing the oligopyrimidine oligopurine target sequence (Py Pu) were amplified by quantitative PCR with primers flanking the Py Pu
sequence (primers Tf and Tb). The amounts of these amplified products (‘target fragments’) were compared to that of the amplified products obtained in the same
sample from a control region (‘control fragments’) (primers Cf and Cb). (Lower panel) The genomic DNA that was 100% modified by Pso-PPT adducts at the
PPT site in the luciferase locus (sample corresponding to lane +hn in Figure 2A) was mixed in various proportions with untreated genomic DNA of CMV(+PPT)/
HeLa cells (1:0; 1:0.25; 1:0.5; 1:0.75; 0:1) in order to obtain defined amounts of triplex-induced adducts (with 100, 75, 50, 25, 0%). Relative PCR inhibition
(amount of amplified luc target fragments/amount of amplified control fragments) is reported as a function of the amount of triplex-induced adducts in the sample
(measured by Dra I protection assay).
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single polymorphism that was not mentioned in the genome
database and that we directly sequenced to understand the
unexpected low TFO binding at this locus. The other target
sequences were then also sequenced and were shown to con-
tain the expected oligopyrimidine oligopurine sequence.
Following digitonin permeabilization, we found that Pso-
PPT-mediated triplex was formed on the different target
genes with various efﬁciencies (Figure 3B): 45% at TRb,
15% at CASK and 0% at non-induced luc; no binding was
detected on the mutated mutCPPT sequence present on
COL4A1 gene. We observed that a silent gene can be either
inaccessible to TFO as it is the case for the non-induced luc
gene, or more surprisingly, highly accessible as it is the case
for the TRb gene. It can also be noticed that the silent TRb
gene is more efﬁciently targeted than the expressed CASK
gene. On the basis of these data it is tempting to suggest
that the transcription itself is dispensable at some chromo-
somal sites for chromatin accessibility to TFOs and that
efﬁcient TFO binding is not necessarily correlated to gene
expression at the target site.
Targeting a determined chromosomal site in different
transcriptional states
Transcription is one of the factors that is known to modify
the chromatin structure. We then studied the inﬂuence of
transcriptional activation and of transcriptional levels of the
target gene on TFO binding in three situations: (i) cell type-
dependent expression; (ii) manipulation of transcriptional
level by treatment with a chemical, here doxycycline; and
(iii) induction of transcriptional activation by Trichostatin
A (TSA) treatment.
The VE-Cadherin gene was chosen as a target because its
expression varied considerably from a cell type to another
(21). It is high in endothelial cells as EA.hy926 cells but
not detectable in HeLa cells (Figure 4A). These two cell
lines were transfected with Pso-CAD via digitonin permeabi-
lization, then irradiated or not. The amount of triplex-induced
adducts just after irradiation was estimated by the PCR-based
method described previously. Weak binding ( 15%) was
detected in non-expressing cells, but it was increased in
expressing cells up to 50%.
The luc gene was used to study another type of transcrip-
tional activation and also to further evaluate TFO binding at
different levels of transcription. CMV(+)PPT/HeLa cells
were treated or not with doxycycline in different conditions
to induce transcription at different levels, and subsequently
permeabilized with digitonin and treated with oligonu-
cleotides (Figure 4B). No binding was detected in the absence
of doxycycline-induced transcription. In contrast targeted
cross-links were considerably enhanced as soon as transcrip-
tion was chemically induced at the target site and they
increased with the transcriptional level of the luc gene. Up
to 50% of chromosomal targets can be speciﬁcally modiﬁed.
However we observed that efﬁciency of triplex formation did
not vary linearly with transcriptional activity and did reach a
plateau of 50%, observed even for a high increase in RNA
levels. It can be noticed that in conditions allowing maximal
coverage of the target site, no binding was detected on the
mutated mutGPPT sequence that is present in the same
transcriptional context within the GFP gene, also under the
control of the CMV doxycycline-inducible promoter.
Finally transcription activation of target genes was induced
by treatment with TSA, a well known histone deacety-
lase inhibitor. The long-term TSA treatment that we used
Figure 3. Efficient TFO binding is not correlated to gene expression at the target site. Triplex formation was evaluated on PPT sequences present at different
genomic loci. The target regions that were PCR-amplified are: luc (integrated luciferase locus), TRb and CASK genes that all contain the PPT15 sequence,
GFP (integrated GFP locus) and COL4A1 genes that contain a mutated PPT sequence (mutCPPT and mutGPPT, respectively) (see precise genomic locations in
Supplementary Data). (A) Genomic DNA of CMV(+PPT)/HeLa cells was treated with Pso-PPT or Pso-CAD TFO, with or without irradiation and the amount of
cross-linked targets was evaluated. (B) CMV(+PPT)/HeLa cells were treated and permeabilized in the presence of Pso-PPT (10 mM) and irradiated. The
percentages of triplex-induced adducts on the different genomic targets were reported. Equivalent levels of triplex formation were obtained in nuclei preparations
(digitonin-permeabilized cells; closed columns) and in whole cells when Pso-PPT was delivered by SLO permeabilization (hatched columns). The expression
status of the target genes was indicated: (+) expressed gene; ( ) no detectable expression.
4550 Nucleic Acids Research, 2006, Vol. 34, No. 16(40 ng/ml for 5 days) has been described and characterized
previously (16): it has been shown to globally increase
histone acetylation, measured using antibodies against
histone H4 acetylated at lysine 5 and 8, and to have a marked
effect on chromatin structure with the possibility to even
unfold highly compact regions. It was used here as a way
to induce expression of the silent genes studied above, VE-
cadherin and luc: for these target genes, such TSA exposure
provoked enhancement of gene transcription and induced
a substantial improvement in the amounts of TFO-modiﬁed
targets (2- and >10-fold for VE-Cadherin and luc, respec-
tively; Figure 4).
Targeting chromosomal sites in whole cells versus
cell nuclei
Works aimed at studying chromatin structure and chromoso-
mal DNA accessibility were mainly performed in nuclei using
preparation that maintain chromosomal structure. Such
approaches were also largely used to quantify TFO binding
in chromatin—including in the present paper—since they
enable uptake limitation to be overcome and deliver large
amounts of TFO in nuclei by passive diffusion through the
nuclear membrane. Here we also evaluated TFO-based chro-
mosomal targeting in whole cells. TFOs were introduced by
streptolysin-O (SLO) reversible permeabilization which is
among the most efﬁcient method existing at present to deliver
oligonucleotides. Thus typically, using an optimized amount
of SLO, around 70% of CMV(+)PPT/HeLa cells were suc-
cessfully permeabilized without marked cell killing (Supple-
mentary Figure 2). TFO binding to the PPT15 sequence
present on luc and TRb genes was determined in whole
cells (Figures 3 and 4, hatched columns). Equivalent results
were obtained with binding efﬁciencies in SLO-permeabilized
living cells of 42% for the doxycycline-activated luc gene and
52% for TRb, compared to 48 and 45% in cell nuclei, respec-
tively. Dependence of TFO binding on luc gene activation
was also observed. These data suggest that targeting of
chromosomal sites by TFOs was mainly limited by the
nuclear environment of the DNA target and not by the cellular
context per se.
DISCUSSION
Triplex-induced activities in cells have been largely reported,
whereas there are few studies that have attempted to provide
direct evidence of TFO binding to chromosomal DNA in
nuclei preparations and even fewer in living cells, as
described here. In all these studies the triplex fraction in trea-
ted cells was from 1 to 30%. Interestingly in two studies the
extent of TFO binding was compared in cell nuclei and in
whole cells (6,11). Binding was strongly decreased and
even abolished in whole cells, most likely due to a reduced
TFO concentration, that could be explained either by poor
transfection or entrapment by cellular proteins. In our experi-
mental conditions we observed equivalent efﬁciencies in the
two settings, nuclei or cells, supporting that there is no intrin-
sic cellular limitation to TFO binding besides the chromatin
structure at the target site. Concerning efﬁciency, we showed
that >50% of a speciﬁc DNA sequence can be successfully
targeted when both TFO chemistry and DNA nuclear environ-
ment are appropriate. TFO/LNAs were recently shown to be
active on transiently transfected templates that might be inef-
ﬁciently assembled into chromatin if at all (15). Here, they
appear to be also efﬁcient to target DNA sequences in a chro-
mosomal environment. However we never observed complete
coverage of the target, consistent with an heterogeneity of the
chromatin structure in the gene population at the time of
analysis (22). Concerning speciﬁcity we provide evidence
Figure 4. Transcriptional activity influences efficiency of TFO binding in some situations. (A) Triplex formation on the VE-Cadherin gene in different cellular
contexts. Percentages of triplex-induced adducts in cell nuclei after treatment with the Pso-CAD (5 mM). Two cells lines were used, either endothelial
(EA.hy926) or CMV(+PPT)/HeLa cells, in absence ( ) or in presence of TSA treatment (+TSA). VE-cadherin expression at the time of TFO administration was
indicated: (+) expressed gene; ( ) no detectable expression. (B) Triplex formation on the integrated target in different transcriptional contexts. Percentages of
triplex-induced adducts on the PPT target (luciferase gene) and on the mutGPPT sequence (GFP gene) in cells (closed columns, cell nuclei; hachted columns,
whole cells). Before TFO addition, different treatments were performed, as indicated. Relative luciferase RNA levels determined just before Pso-PPT addition
were reported; ( ) means that the gene is not expressed, with an RT–PCR signal close to the background level.
Nucleic Acids Research, 2006, Vol. 34, No. 16 4551that irrelevant TFO sequences were inactive and also, highly
important and rarely done, that mutated targets, containing
mutations, were inefﬁciently recognized, both in naked
DNA and in chromatin (Figures 3 and 4).
Different approaches have been described to quantify TFO
binding in genomic DNA. They all make use of TFOs cova-
lently linked to a reactive moiety and measure the amount of
triplex-induced modiﬁcation at the target site. Here we have
developed a quantitative PCR-based assay that is robust,
consumes little material and is also much more rapid than
methods described already, including PCR-related ones. It
is based on PCR inhibition produced by an inter-strand
DNA lesion, a cross-link in our case, when using primers
around the damaged site. The level of PCR inhibition directly
reﬂects the amount of modiﬁed targets. We have validated it
by comparison with two already established methods, both
restriction enzyme protection assay associated with Southern
blotting and competitive PCR. Then the described approach
will be useful to determine DNA accessibility to TFOs at
different genomic sites and to measure a large variety of
site-directed DNA lesions, as well.
Using this method, we have explored some of the mecha-
nisms enabling accessibility of chromosomal DNA to TFOs.
To address this question we have studied two types of situa-
tions that are discussed below.
We have ﬁrst examined the inﬂuence of various chromo-
somal contexts. The same TFO was used to target the oligo-
pyrimidine oligopurine PPT sequence that is present in
different genes. Binding efﬁciency did vary from one gene
to another and was not correlated with the fact that the
gene is expressed or not, since a silent gene, such as TRb
in HeLa cells, can be efﬁciently targeted. There would be
at least two possible explanations for such accessibility to
TFO of the silent TRb sequence. One is that it might be
located in an unfolded large-scale chromatin structure pro-
duced independently of transcription, as already proposed
in other systems (23). A second possibility is that antisense
transcription from the strand opposite to the coding strand
might occur within the target region, even if such RNA
species has not been presently described to our knowledge.
Then we have further characterized the role of transcrip-
tion, by studying targeting of a given gene by TFOs in
different transcriptional contexts. Transcriptional inﬂuence
on triplex formation in chromatin was already reported but the
results are apparently contradictory. In the case of a lacZ
transgene, an increase in TFO binding was observed in cell
nuclei after a 250-fold activation of target gene expression,
measured at the protein level (8). However, in two other stud-
ies, treatments known to enhance transcription did not affect
the level of triplex formation (3,5). In this work we have
observed two major situations. On one hand we have demon-
strated that transcriptional activation enhanced TFO access to
chromatin in the case of a silent gene that is not or weakly
accessible to a TFO, such as luc and VE-cadherin genes,
respectively. Such transcriptional dependence was observed
for different types of activation and at integrated and endoge-
nous chromosomal loci; it seems to be a general phenom-
enon. It must be noticed that we report that it is possible to
speciﬁcally and efﬁciently target a gene in its active state
without targeting the silent state. Our data support an
increased access to TFO of transcribed regions, where the
oligopyrimidine oligopurine targets are located, following
transcriptional activation. The role of this latter phenomenon
in opening chromatin structure was extensively documented
in the promoters but also, even if more rarely, in transcribed
regions (24). On the other hand, we have shown that beyond a
certain level of transcriptional activity, an additional increase
had no impact on efﬁciency of targeting by TFOs. In fact, tar-
geting an inducible gene whose transcription can be precisely
controlled, we observed that TFO binding started to increase
with transcriptional activity and ﬁnally reached a plateau.
These data suggest that for highly transcribed genes, further
increase in transcription might have no effect on triplex
formation. This type of result can explain the apparently
inconsistent data reported previously [(3,5) compared to
(8)]. It would be due to the RNA polymerase helicase activity
that could remove the triplexes, as described for other heli-
cases, and reduce the probability of triplex formation during
the irradiation. It is also relevant in the light of recent ﬁndings
describing that above a certain level of transcription and RNA
pol II density, histones lose contact with DNA and efﬁcient
re-establishment of histone–DNA contacts after polymerase
passage might not be possible, resulting in a net loss of
nucleosomes.
Together it is tempting to suggest that TFO binding is efﬁ-
cient in open chromatin and may occur competitively with
nucleosome binding, enlarging in vitro data obtained with
reconstituted nucleosomes. To support this model, chromatin
accessibility of the targeted locus was assessed by using a
standard restriction enzyme accessibility test. We chose to
study the luciferase locus that is appropriate for Dra I anal-
ysis. We showed that chromatin access within this locus par-
alleled the percentage of triplex-induced adducts: no Dra I
cleavage of the luc gene was observed in nuclei of non-
activated cells, whereas luc gene was cleaved after doxycy-
cline activation (Dox2 treatment; data not shown). Finally,
we reported a strong increase in TFO binding following
TSA treatment that induced transcriptional activation of the
target gene, likely by increasing histone acetylation. These
data suggest that it may exist a relation between histone
acetylation and more generally the nature of histone modiﬁ-
cations in the vicinity of the target site and the efﬁciency
of TFO binding. Indeed it appears more and more clearly
that the ‘histone code’ that deﬁnes silent, active, accessible
chromatin regions is more complicated than expected and
likely results in a combination of histone modiﬁcations
[e.g. (25)]. The combination(s) deﬁning chromatin regions
that are accessible to DNA ligands such as TFOs remains
to be determined.
In conclusion, the results presented here have practical sig-
niﬁcance for triplex-based strategies. Among oligonucleotide
technologies, TFOs offer unique potential as DNA binding
molecules that recognize speciﬁc sequences in chromatin.
They would be useful both for positioning DNA interacting
or reactive compounds, such as anticancer drugs, based on
chemical conjugation of these reagents to TFOs, and for
probing chromatin structure and function. On one hand, our
data suggest that targeting of a gene which is speciﬁcally
expressed under some physiological conditions, e.g. during
tumor development, might occur preferentially in the
conditions of active transcription. This will be an important
consideration for speciﬁc targeting of some tumor-associated
4552 Nucleic Acids Research, 2006, Vol. 34, No. 16genes in cancer versus normal cells. On the other hand, TFOs
can also efﬁciently access to chromatin at silent or weakly
expressed genes and likely at intergenic regions. These results
will encourage the use of TFO/LNA as synthetic tools for
investigating fundamental questions of chromosome biology
at these loci.
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